

**For Immediate Release***Media:*

Mary Ellen DeFrancesco  
301-617-9080 x 227

*Investors:*

Michael Thomas  
301-617-9080 x 233

**MetaMorphix, Inc. Announces Appointment of Fergus Reid to Board of Directors**

—Distinguished Investment Banker Brings Over 23 years of Expertise to MetaMorphix Board —

***Savage, Md., November 13, 2002***—MetaMorphix, Inc. announced today that Fergus Reid Chairman of the JP Morgan/Chase Mutual Funds and a trustee of the Morgan Stanley Mutual Funds has joined the Company's board of directors. Reid serves as Chairman and CEO of Lumelite Corporation, a privately held, plastics manufacturing company and has over 23 years of experience as an investment banker.

"We are delighted and fortunate to have Fergus Reid join us", said Edwin C. Quattlebaum, Chairman and CEO of MetaMorphix Inc. "The existing Board has a wealth of experience in the fields of biotechnology, finance, animal health and livestock production. The addition of Fergus, with his distinguished career as an investment banker and his continued involvement in capital markets will provide MetaMorphix the investment banking expertise that will be invaluable when undertaking an IPO," continues Quattlebaum. "The board also recognizes Fergus' experience operating a small, privately held organization as an added resource balanced against the substantial large company experience of other directors. "

Reid began his professional career in 1959, after graduating from Yale University and serving in the US Army as an Airborne Officer in Germany, with Roosevelt & Son, a New York bond firm. There he took on increasingly responsible roles until he was appointed President and CEO. The firm merged with Kidder Peabody under his stewardship in 1973 and Reid left to join Clark Dodge & Company as the Chairman of its Fixed Income Group. In 1974, he joined Rickerfeller Family and Associates. He went on to become the Managing Director of Bernhard Associates, a venture capital firm, in 1982. 1985, Reid acquired and continues to run Lumelite, a manufacturing company specializing in plastics for the automotive, pharmaceutical and cosmetic industries.

In addition to his prior board appointments with such organizations as the Park Avenue funds-Chase Manhattan Bank and Dreyfus National Bank and Trust Company, Reid has been a trustee of the American Museum of National History, South Street Seaport Museum and the Vincent Astor Foundation. He has also served as the chairman of the Hudson River Valley Commission and vice chairman of the NYC Educational Construction Fund.

The appointment of Fergus Reid continues MetaMorphix's objective to maintain a board of diverse industry leaders that speaks to the company's various audiences.

## METAMORPHIX INC. BOARD OF DIRECTORS

---

### Biotechnology

Clifton Baile, Ph.D.  
Eminent Scholar in Agricultural Biotechnology,  
University of Georgia  
*Former Director of R&D,  
Monsanto Company, Animal Health*

Edwin C. Quattlebaum, Ph.D.  
Chairman, President & CEO,  
MetaMorphix, Inc.

### Investment/Financial

Fergus Reid  
Chairman & CEO,  
Lumelite Corp.  
Chairman,  
J.P.Morgan/Chase Mutual Fund.  
Trustee,  
Morgan Stanley Mutual Fund

Ugo DeBlasi  
VP and CFO,  
Celera Genomics

### Animal Health Industry

Thomas Parton  
*Former Managing Director,  
Ciba Geigy Agricultural Division*

Gerald Welch  
*Former Executive Vice President,  
Allied Businesses  
The Upjohn Co.*

### Livestock Industry

John Block  
President,  
Food Distributors International  
*Former U.S. Secretary of Agriculture*

Leland Tollett  
*Former Chairman & CEO,  
Tyson Foods, Inc.*

Peter Meyer  
President,  
PMI Consultants  
*Former VP Sales & Marketing  
Archer Daniels Midland, Corp.*

### About MetaMorphix, Inc.

Founded in 1994 and based in Savage, Maryland, MetaMorphix, Inc., a privately held life sciences company, is dedicated to discovering and commercializing multiple technology platforms to naturally improve the food supply and human health.

Drawing on three distinct technology platforms – growth differentiation factors (GDFs), genomics/proteomics and immunopharmaceuticals – MetaMorphix has more than a dozen products in various stages of development. These products are intended to vastly improve livestock breeding and production and to create more nutritious, consistent-quality meat. Further, the company is leveraging a licensing agreement, using its GDF technology platform, to research potential applications to serious human health conditions.

*Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “intend,” “anticipate,” “should,” “planned,” “estimated,” and “potential,” among others. These forward-looking statements are based on MetaMorphix Inc.’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, MetaMorphix Inc. notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of MetaMorphix Inc.’s businesses include but are not limited to; (1) unproven use of scientific information to develop or commercialize products; and (2) other factors that might be described from time to time in MetaMorphix Inc.’s business plan and regulatory filings.*



